行情

NVAX

NVAX

诺瓦瓦克斯医药
NASDAQ

实时行情|Nasdaq Last Sale

7.72
-0.22
-2.77%
盘后: 7.80 +0.08 +1.04% 17:24 02/21 EST
开盘
7.87
昨收
7.94
最高
7.94
最低
7.63
成交量
180.45万
成交额
--
52周最高
43.40
52周最低
3.540
市值
2.48亿
市盈率(TTM)
-1.0847
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NVAX价格均价为13.75,最高价位27.50,最低价为6.00。

EPS

NVAX 新闻

更多
  • These are the steps needed for a vaccine to be approved
  • MarketWatch · 2天前
  • Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
  • Zacks · 3天前
  • Sanofi Gets Backing From U.S. Government to Develop a COVID-19 Vaccine
  • MotleyFool.com · 4天前
  • 6 Healthcare Stocks That Could Make You Filthy Rich
  • MotleyFool.com · 5天前

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

NVAX 简况

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
展开

微牛提供Novavax, Inc.(NASDAQ-NVAX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NVAX股票新闻,以帮助您做出投资决策。